Where feasible, integration (of measles campaigns) may be considered with other mass vaccination, such as polio vaccination, and with vitamin A supplementation. However, integration with other such interventions must not compromise the quality of measles SIAs.

An extra volunteer or health worker must be budgeted for and made available for each additional intervention included in the measles SIAs.

Examples of public health interventions that have been integrated with measles SIAs include:
• Injectables: rubella vaccine, yellow fever vaccine, tetanus toxoid; for these, immunization safety and injection safety issues must be implemented with utmost care.
• Orally-administered medication or interventions: oral polio vaccine (OPV), vitamin A, anthelminthic treatment.
• Others: distribution of insecticide-treated nets.

All yellow fever immunization activities aim to ensure a minimum coverage of at least 80%. These include:
A) Prevention: by administering yellow fever vaccine as part of routine infant immunization; control of Aedes aegypti mosquitoes in urban centres, and preventing outbreaks in high-risk areas through mass campaigns.
B) Control: by instituting a sensitive and reliable yellow fever surveillance system including laboratory capacity to analyse samples and confirm suspected cases; and emergency response to outbreaks through mass campaigns.
The main strategies to control yellow fever are based on a combination of immunization for protection against the disease and surveillance, and are outlined below.

Prevention:
- administering yellow fever vaccine as part of routine infant immunization;*
- preventing outbreaks in high-risk areas through mass campaigns;*
- control of Aedes aegypti in urban centres.
* Both these strategies should ensure a minimum coverage of at least 80%.

Control
- instituting a sensitive and reliable YF surveillance system including laboratory capacity to analyse samples and confirm suspected cases;
- emergency response to outbreaks through mass campaigns.

WHO recommends a two-pronged strategy for YF (yellow fever) prevention: the incorporation of YF vaccination as part of routine infant immunization, and mass preventive campaigns to immunize persons who have not previously had access to YF vaccine.

In countries at risk for YF (yellow fever), the use of the 17D vaccine is the main strategy recommended to rapidly build up YF immunity in the population at large. This prevention strategy has two components. The first component is the inclusion of the 17D vaccine in national childhood immunization programmes.

The second component is the implementation of mass preventive vaccination campaigns to protect susceptible older age groups. In the event of limited resources, assessment of the degree of risk can help prioritize areas for mass preventive campaigns.
Yellow Fever

YF (yellow fever) vaccine should be offered to all travellers to and from at-risk areas, unless they belong to the group of individuals for whom YF vaccination is contraindicated. There is currently insufficient scientific evidence to support a change in the International health regulations for travelers to endemic areas demanding proof of valid YF vaccination within the preceding ten years. However, in at-risk countries, vaccination resources should be directed to ensuring good primary vaccination coverage rather than to providing booster doses.

Given the very rare, but potentially severe, adverse effects, YF (yellow fever) vaccine for travellers should be administered on strict indications only, particularly in the elderly. Restriction of YF vaccination to authorized centres is likely to promote the appropriate use of YF vaccine.

To avoid devastating outbreaks of YF (yellow fever) in the future, YF vaccine must be fully introduced into well functioning childhood vaccination programmes. In addition, childhood vaccination should be combined with pre-emptive YF vaccination campaigns in at-risk areas, and in urban areas control efforts directed against Aedes aegypti should be increased. In areas of predominantly jungle-type transmission, YF vaccination of persons belonging to the high-risk groups is strongly recommended.

WHO’s recommended strategy for (yellow fever) outbreak prevention is:
- providing YF vaccine as part of routine infant vaccination; and
- preventive mass-immunization campaigns in high-risk districts.

The strategy for (yellow fever) outbreak control is:
- strengthening case-based surveillance including laboratory capacity to confirm suspected cases; and
- strengthening outbreak response through improved epidemic preparedness.

**Procurement**

Mechanisms should be found to provide incentives for manufacturers of YF (yellow fever) vaccine to sustain or increase their production capacity to ensure rapid delivery of sufficient quantities in the event of a major YF outbreak.

_Yellow fever vaccine (WHO position paper)_

Concerned international organizations have agreed to build up an emergency stockpile of YF (yellow fever) vaccine that should be retained for outbreak response in Africa and South America. A stockpile of 6 million doses is now reserved for this purpose.

_Yellow fever vaccine (WHO position paper)_

**Vaccine Quality**

(Yellow fever vaccines) meeting the WHO stability guidelines show a minimum mouse potency titer (or an equivalent potency in PFU) of greater than 1000 units after exposure to 37°C for 14 days, and their loss in potency during this exposure is less than 1 log10.

_Temperature sensitivity of vaccines_
**Yellow Fever**

According to current WHO requirements, a YF (yellow fever) vaccine that has been held at 37 °C for 14 days must (i) maintain the minimal potency of >1000 MLD50 per dose and (ii) show a mean loss of titre <1 log 10 MLD50. These requirements necessitate the addition of stabilizers such as sorbitol and gelatin.

Yellow fever vaccine (WHO position paper)  
Page 355

---

### Vaccine Handling

The recommended conditions for storing vaccines used in immunization programmes are shown in Appendix 81.1. This diagram also indicates the maximum times and temperatures in each case. At the higher levels of the cold chain, i.e., at national (primary), and regional or province level, OPV must be kept frozen between -15oC and -25oC. Freeze-dried vaccines (i.e., BCG, measles, MMR and yellow fever) may also be kept frozen at -15oC to -25oC if cold chain space permits, but this is neither essential nor recommended. At other levels of the cold chain (intermediate vaccine stores and health facilities), these vaccines should be stored between +2oC and +8oC. All other vaccines should be stored at between +2oC and +8oC at all levels of the cold chain. Liquid formulations of vaccines containing diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenzae type b, IPV and their combinations should not be frozen.

Regardless of stability of a reconstituted vaccine (including yellow fever), because of the risk of contamination, such products should be kept cold after reconstitution and discarded at the end of a 6-hour immunization session.

---

26 November 2007  
Page 5 of 23
Yellow Fever

Yellow fever vaccine should be quickly administered after reconstitution, maintained at 2-8°C, and discarded at the end of the session, not only to preserve potency, but to minimize risk of contamination of this lyophilized vaccine once reconstituted.

WHO recommended vaccine storage conditions (Appendix 17_3).

WHO no longer recommends that freezedried vaccines (measles, yellow fever, Hib and BCG) be shipped and stored at -20°C. Storing them at -20°C is not harmful but is unnecessary. Instead, these vaccines should be stored and transported at +2°C to +8°C.

It is essential that only the diluent supplied with the (yellow fever) vaccine be used.

Reconstituted (yellow fever) vaccine must be kept at 2°C - 8°C and discarded after six hours or at the end of the immunization session, whichever comes first.

The lyophilized (YF) vaccine requires proper storage under cold-chain conditions, and reconstituted vaccine must be kept on ice and used within six hours.
At the higher levels of the cold chain, i.e. at the national (central) and regional or provincial levels, OPV must be kept frozen between -15°C and -25°C.

Freeze-dried vaccines, i.e. BCG, measles, MMR and yellow fever vaccines, may also be kept in this temperature range (-15°C and -25°C) if there is sufficient space in the cold chain, but this is neither essential nor recommended. At other levels of the cold chain these vaccines should be stored between +2°C and +8°C. All other national immunization service vaccines should be stored between +2°C and +8°C at all levels of the cold chain.

**Ensuring the quality of vaccines at country level: Guidelines for health staff**

Reconstituted BCG, measles and yellow fever vaccines must be kept cooled and must be discarded after 6 hours after reconstitution.

Proper handling and reconstitution of vaccines avoids programme errors

It is no longer necessary to ship and store freeze-dried vaccines (measles, yellow fever and BCG) at −20°C. Instead, they may be refrigerated at +2°C to +8°C.

Proper handling and reconstitution of vaccines avoids programme errors

WHO no longer recommends that freeze-dried vaccines (measles, yellow fever, Hib and BCG) be shipped and stored at −20°C. Storing them at −20°C is not harmful but is unnecessary and uses up valuable storage space in the deep-freeze. Instead, they should be kept in refrigeration and transported at +2°C to +8°C.

Proper handling and reconstitution of vaccines avoids programme errors

Yellow fever vaccine can safely be stored at -20°C or +4°C for two years or more.

Thermostability of vaccines
**Yellow Fever**

Lyophilized yellow fever vaccine can be safely stored at -20°C or +4°C for two years.

Thermostability of vaccines

Yellow fever vaccine should be quickly administered after reconstitution (up to one hour). If the reconstituted vaccine is kept continuously in an ice bath, it can be used within one immunization session but must be discarded at the end of the session.

Thermostability of vaccines

Reconstituted vaccines against measles, yellow fever and tuberculosis (BCG) are unstable vaccines; they should be used as soon as possible after reconstitution, be kept in a ice bath during the immunization session and should be discarded at the end of the session.

Thermostability of vaccines

---

**Multi-dose Open Vials**

Opened vials of measles, yellow fever and BCG vaccines MUST be discarded at the end of each immunization session or after 6 hours whichever comes first.
Opened vials of measles, yellow fever, BCG and freeze-dried Hib vaccine cannot be used after an initial immunization session, (even if the VVM has not reached the discard point.). They must be discarded within six hours of reconstitution or at the end of the session, whichever comes first. The VVMs for these vaccines are attached to the vial caps and should be discarded when the vaccine is being reconstituted.

**Schedule**

WHO recommends the following schedule for infants (Appendix 39_5).

GACVS reiterates that particular care should be taken that the (17D yellow fever) vaccine is received only by those travellers who are truly at risk of exposure to yellow fever. In addition, vaccine providers should give careful consideration to the risks and benefits for elderly travellers and should routinely enquire about a history of thymus disorder, irrespective of the age of the subject. Where a history of thymus disorder is reported, alternative prevention measures should be considered.

Global Advisory Committee on Vaccine Safety, 2–3 December 2004

**Yellow Fever**
Yellow Fever

Typical immunization schedule for children (see Appendix 2_19.)

Immunization in practice: a practical resource guide for Health workers – 2004 update Module 2: The vaccines

Yellow fever vaccination for the purposes of international travel is geared towards protecting non-infected countries from importation of the virus. Thus a conservative approach is still deemed necessary and 10-year booster shots should be maintained in this situation. However, in endemic countries, it is preferable to prioritize efforts to achieve good primary coverage rather than booster doses.


(YACVS stated that) particular care should be taken that the (yellow fever) vaccine is received only by those travellers truly at risk for yellow fever exposure. Furthermore, care should be taken that routine yellow fever vaccination programmes are not jeopardized by risk–benefit ratios that may be inapplicable to the target populations in endemic countries.

Global Advisory Committee on Vaccine Safety, 3–4 December 2003

(YF (yellow fever) vaccine should be offered to all travellers to and from at-risk areas, unless they belong to the group of individuals for whom YF vaccination is contraindicated. There is currently insufficient scientific evidence to support a change in the International health regulations for travelers to endemic areas demanding proof of valid YF vaccination within the preceding ten years. However, in at-risk countries, vaccination resources should be directed to ensuring good primary vaccination coverage rather than to providing booster doses.

Yellow fever vaccine (WHO position paper)
**Yellow Fever**

All persons aged 9 months or older and living in YF (yellow fever) at-risk areas should receive YF vaccine. Highest priority should be given to those persons most likely to be exposed, such as forestry and agricultural workers, and to those living in villages or towns with a history of previous outbreaks. Immigrants to such regions from non-endemic areas should also be vaccinated against YF.

Travellers should be vaccinated at least 10 days before arrival in the at risk area.

---

**Yellow fever vaccine (WHO position paper)**

---

In countries at risk of YF (yellow fever), YF vaccine is recommended for use in all children aged at least 9-12 months of age. In addition, preventive vaccination of older children and adults is recommended in at risk areas. Vaccination for YF is also recommended for travellers aged above 9 months who plan to visit areas at risk for YF.

---

According to the International health regulations and the WHO International certificate of vaccination, a booster dose of YF (yellow fever) vaccine is required every 10 years. However, in most cases, the duration of protection following the first dose of YF vaccine seems to be at least 30-35 years and possibly lifelong. For this reason, it has been proposed to limit vaccination against YF to a single dose. In order to clarify this matter, WHO organized a consultation with a group of YF experts in March 2003. This group reviewed relevant literature and available data and concluded that, at present, the evidence for protective immunity beyond 10 years was insufficient to justify a change in the current YF vaccination policy for international travellers. However, in at-risk countries, vaccination resources should be directed to ensuring good primary vaccination coverage rather than to providing booster doses. For the purposes of international travel, only YF vaccinations performed at nationally authorized YF vaccination sites and using WHO pre-qualified YF vaccines may be entered into the International Certificate of Vaccination.

---

Given the very rare, but potentially severe, adverse effects, YF (yellow fever) vaccine for travellers should be administered on strict indications only, particularly in the elderly. Restriction of YF vaccination to authorized centres is likely to promote the appropriate use of YF vaccine.
**Yellow Fever**

The (YF) vaccine is also widely used for the protection of travelers to YF-endemic areas. (YF vaccine (WHO position paper)

---

**Vaccine Administration**

For the countries where yellow fever is endemic, the vaccine can be routinely administered at the time of measles vaccination. If yellow fever vaccine is not administered at the same time as measles vaccine, to assure an optimal immune response, it is generally recommended that there is at least a one month interval between measles and yellow fever vaccination. (Global field guide for planning and implementing measles supplementary immunization activities)

---

**Administration summary: YF vaccine (see Appendix 2_17.)**

**Yellow Fever**

See Appendix 6_19 for chart entitled, "Administering vaccines to infants" BCG, DTP, DTP-HepB, HepB, measles, yellow fever, OPV"

For convenience and improved coverage, the YF vaccine should be administered simultaneously with the measles vaccine at approximately 9-12 months of age, but in a separate syringe and at a different injection site.

The YF (yellow fever) vaccine is given as a single subcutaneous or intramuscular injection (0.5 ml per dose), although the subcutaneous route is preferred.

**Contraindications**

Yellow fever vaccine is contraindicated for infants less than 6 months of age, immune-deficient persons and persons with egg allergy. The risk of disease should be weighed against the risk of vaccination in pregnant women and in persons with symptomatic HIV infection. These are important factors to consider before planning a mass preventive vaccination campaign.
**Yellow Fever**

GACVS reiterates that particular care should be taken that the (17D yellow fever) vaccine is received only by those travellers who are truly at risk of exposure to yellow fever. In addition, vaccine providers should give careful consideration to the risks and benefits for elderly travellers and should routinely enquire about a history of thymus disorder, irrespective of the age of the subject. Where a history of thymus disorder is reported, alternative prevention measures should be considered.

Global Advisory Committee on Vaccine Safety, 2–3 December 2004

All infants should be immunized except in these three rare situations:
1. Anaphylaxis or a severe hypersensitivity reaction is an absolute contraindication to subsequent doses of a vaccine. Persons with a known allergy to a vaccine component should not be vaccinated.
2. Do not give BCG or yellow fever vaccine to an infant that exhibits the signs and symptoms of AIDS.

Immunization in practice: a practical resource guide for Health workers – 2004 update Module 2: The vaccines

Those who have a severe reaction (to yellow fever vaccine) should not receive additional doses.

Immunization in practice: a practical resource guide for Health workers – 2004 update Module 2: The vaccines

All infants should be immunized except in these three rare situations:
1. Anaphylaxis or a severe hypersensitivity reaction is an absolute contraindication to subsequent doses of a vaccine. Persons with a known allergy to a vaccine component should not be vaccinated.
2. Do not give BCG or yellow fever vaccine to an infant who exhibits the signs and symptoms of AIDS (see Appendix 6_11A). Other vaccines should be given.
3. If a parent strongly objects to an immunization for a sick infant, do not give it. Ask the mother to come back when the infant is well.

The following are not contraindications. Infants with these conditions should be immunized (see Appendix 6_11B)

(GACVS stated that) particular care should be taken that the (yellow fever) vaccine is received only by those travellers truly at risk for yellow fever exposure. Furthermore, care should be taken that routine yellow fever vaccination programmes are not jeopardized by risk–benefit ratios that may be inapplicable to the target populations in endemic countries.

A critical and unresolved issue is the safety and efficacy of yellow fever vaccine in human subjects infected with immunodeficiency virus (HIV). It remains to be determined whether HIV-positive status materially affects seroconversion, the risk of invasion of the nervous system and of encephalopathy, the stage of HIV disease at which yellow fever vaccination should be contraindicated, and whether there are differences in the incidence of minor and major adverse effects in HIV-positive subjects.

The (yellow fever) vaccine is contraindicated in children aged under 6 months and is not recommended for those aged 6-8 months, except during epidemics when the risk of YF virus transmission may be very high. It is also contraindicated for persons with severe allergy to egg and for severely immunocompromised persons. On theoretical grounds, the 17D vaccine is not recommended during pregnancy. However, pregnant women may be vaccinated during epidemics when the risk of YFV transmission may be very high.
Contraindications against YF vaccination include age less than 6 months, severe hypersensitivity to egg antigens and severe immunodeficiency. Whereas it is relatively easy to avoid immunization of the first two categories, the principal contraindications against immunization during pregnancy and in severe immunodeficiency cause significant practical problems. Fortunately, the few published cases of congenital infection caused by 17D have not been associated with fetal abnormalities. Similarly, no adverse events occurred in a small study of HIV-infected children with low CD4+ counts who received the vaccine. These observations are important considering the likelihood that many pregnant women and HIV-positive individuals, including children, will be immunized inadvertently during large-scale immunization activities in at-risk countries.

For international travellers, where laboratory and other resources are available, YF (yellow fever) vaccination may be offered to asymptomatic HIV-infected persons with CD4+ counts above 200 cells/mm³ who require vaccination for unavoidable travel. Individual expert assessments are required before YF vaccination may be offered to persons taking high-dose corticosteroids or antineoplastic drugs. If possible, tests should be performed to ensure that protective levels of neutralizing antibodies have been achieved, as primary vaccination failure is common in immunodeficient individuals.

Given the very rare, but potentially severe, adverse effects, YF (yellow fever) vaccine for travellers should be administered on strict indications only, particularly in the elderly. Restriction of YF vaccination to authorized centres is likely to promote the appropriate use of YF vaccine.

(With yellow fever vaccine,) if a serious reaction does occur, health workers should report the problem to supervisors immediately.
Adverse events following YF (yellow fever) vaccination are usually minor, although hypersensitivity to vaccine components may occasionally occur, and very rare cases of viral encephalitis or multiple organ failures have been reported. The rare adverse events should not deter the appropriate use of this highly valuable vaccine.

Improved surveillance and reporting of any potential adverse event following (yellow fever) vaccination is recommended in order to correct any programmatic errors that may be involved and to facilitate improved understanding of the pathogenic mechanisms causing the recently described serious adverse events.

When promoting increased use of YF (yellow fever) vaccine in at risk areas, the outstanding safety and effectiveness profile, the long duration of protection and the cost-effectiveness of the 17D vaccine should continue to be emphasized. However, recent reports of severe, but very rare, vaccine-associated adverse events highlight the importance of careful post-licensure surveillance, even for well established vaccines. Enhanced surveillance of such events and careful molecular analyses of the 17D strains isolated from potential new cases as well as from the actual vaccine batches should contribute to the understanding of the pathogenetic mechanisms involved.

The issue of deaths following YF (yellow fever) vaccination was highly sensitive where few YF cases exist, and vaccination should be postponed in such countries. WHO believed the vaccine to be safe but more data were necessary.
Outbreak Control

All yellow fever immunization activities aim to ensure a minimum coverage of at least 80%. These include:
A) Prevention: by administering yellow fever vaccine as part of routine infant immunization; control of Aedes aegypti mosquitoes in urban centres, and preventing outbreaks in high-risk areas through mass campaigns.
B) Control: by instituting a sensitive and reliable yellow fever surveillance system including laboratory capacity to analyse samples and confirm suspected cases; and emergency response to outbreaks through mass campaigns.

Global field guide for planning and implementing measles supplementary immunization activities

For yellow fever:
- All suspected cases and outbreaks should be investigated immediately and blood samples should be collected for laboratory confirmation.
- Case-based surveillance should be implemented in countries identified by WHO as being at risk for yellow fever. Specimens should be collected to confirm epidemics as rapidly as possible. Priority should then be given to collecting specimens from new or neighbouring areas (other than the areas where epidemics are already confirmed).

WHO–recommended standards for surveillance of selected vaccine-preventable diseases

During YF (yellow fever) epidemics, outbreak response vaccination campaigns should be carried out with minimum delay in order to limit the spread of the disease. The occurrence of an epidemic reflects incomplete implementation of prevention strategies, which therefore need to be strengthened following the outbreak. Appropriate measures to control Ae. Aegypti should accompany all efforts to improve immunization coverage.

Page 356: During YF outbreaks, mass immunization should be instituted at the earliest possible stage and according to locally defined priorities.

Yellow fever vaccine (WHO position paper)
Yellow Fever

The (yellow fever) vaccine is contraindicated in children aged under 6 months and is not recommended for those aged 6-8 months, except during epidemics when the risk of YF virus transmission may be very high. It is also contraindicated for persons with severe allergy to egg and for severely immunocompromised persons. On theoretical grounds, the 17D vaccine is not recommended during pregnancy. However, pregnant women may be vaccinated during epidemics when the risk of YFV transmission may be very high.


In countries at risk for YF, this vaccine is recommended for individual and outbreak prevention as well as outbreak control. At risk for yellow fever is defined as areas where evidence for presence of the virus has been demonstrated and where ecological factors can support yellow fever virus transmission to man.


Immunization Coverage

All yellow fever immunization activities aim to ensure a minimum coverage of at least 80%.

Global field guide for planning and implementing measles supplementary immunization activities WHO/IVB/04.24 Page 14
Another challenge for (yellow fever vaccine) introduction is maintaining high vaccination coverage, as at least 80% of the infants need to be vaccinated for effective disease control.

Surveillance of Vaccine Preventable Disease

All yellow fever immunization activities aim to ensure a minimum coverage of at least 80%. These include:

A) Prevention: by administering yellow fever vaccine as part of routine infant immunization; control of Aedes aegypti mosquitoes in urban centres, and preventing outbreaks in high-risk areas through mass campaigns.

B) Control: by instituting a sensitive and reliable yellow fever surveillance system including laboratory capacity to analyse samples and confirm suspected cases; and emergency response to outbreaks through mass campaigns.

Yellow fever surveillance is therefore critical for monitoring the incidence of the disease and allowing the prediction and early detection of outbreaks and the monitoring of control measures. Case-reporting of yellow fever is universally required by the International Health Regulations.
Yellow Fever

Recommended types of surveillance for yellow fever:
1) Routine monthly reporting of aggregated data on suspected and confirmed cases form the peripheral level to the intermediate and central levels.
2) Designated reporting sites at all levels should report at a specified frequency (e.g. weekly or monthly) even if there are zero cases (often referred to as “zero reporting”).
3) Immediate reporting of suspected cases from the peripheral level to the intermediate and central levels.
4) All suspected cases and outbreaks should be investigated immediately and blood samples should be collected for laboratory confirmation.
5) Case-based surveillance should be implemented in countries identified by WHO as being at risk for yellow fever. Specimens should be collected to confirm epidemics as rapidly as possible. Priority should then be given to collecting specimens from new or neighbouring areas (other than the areas where epidemics are already confirmed).

Note: The international Health Regulations require all yellow fever cases to be reported to WHO within 24 hours of detection.
The various clinical presentations of YF (yellow fever) may be mistaken for those of a number of other infectious diseases that occur in YF at-risk countries. This underscores the importance of having a sensitive, case-based YF surveillance system, supported by laboratory diagnostic facilities. The timely notification and investigation of patients with acute febrile illness and jaundice, with or without haemorrhagic manifestations, is recommended to increase the sensitivity of surveillance to detect the circulation of YF virus. The early detection of YF virus circulation would prompt timely implementation of outbreak response activities.

When promoting increased use of YF (yellow fever) vaccine in at-risk areas, the outstanding safety and effectiveness profile, the long duration of protection and the cost-effectiveness of the 17D vaccine should continue to be emphasized. However, recent reports of severe, but very rare, vaccine-associated adverse events highlight the importance of careful post-licensure surveillance, even for well-established vaccines. Enhanced surveillance of such events and careful molecular analyses of the 17D strains isolated from potential new cases as well as from the actual vaccine batches should contribute to the understanding of the pathogenetic mechanisms involved.

WHO recognizes the urgent need for improved surveillance of YF (yellow fever) in at-risk countries. There is therefore an urgent need for rapid laboratory confirmation of diagnosis in clinically suspected cases. WHO recommends extended use of the filter-paper method for blood collection because it improves safety of the procedure and simplifies both collection and transportation of the samples. Dried blood on filter-paper allows testing for PCR products as well as for YF virus-specific IgM.
Yellow Fever

Introduction of Vaccines

Yellow fever vaccine is recommended as part of the routine national immunization programme in countries where the disease is endemic.

In 1988, the joint United Nations Children's Fund/WHO Technical Group on Immunization in Africa recommended that countries at risk for YF (yellow fever) incorporate the 17D vaccine into their national immunization programme.

Noting that routine yellow fever vaccination is endorsed by the World Health Assembly, SAGE strongly endorses the additional strategy of targeting “high-risk” districts for both routine infant immunization and conducting one-off “catch-up” campaigns. These campaigns target persons 9 months of age and above for YF vaccination. It is helpful to have a well-functioning routine immunization system before conducting a preventive mass campaign. However, it is not necessary to wait for YF vaccine to be included in the routine immunization system before conducting such a campaign (so long as there is not a long interval between the two activities). Indeed, a campaign can be used as an opportunity to “jump-start” the inclusion of YF vaccine in routine immunization services.